However, ERK inhibitors, such as RAF and MEK inhibitors, have shown poor results in clinical trials treating patients with KRAS-mutant tumors, especially those with KRAS-mutant CRC. This evidence concerns the gene MAP2K7 and colorectal carcinoma.